Holen Sie sich die Stockscreener-App
60.49
2.09%
1.24
Halozyme Therapeutics Inc Aktie (HALO) Neueste Nachrichten
Halozyme Sues Merck Over Subcutaneous Keytruda Formulation, Seeks Injunctive Relief - MSN
H.C. Wainwright maintains Buy on Halozyme stock, $72 target By Investing.com - Investing.com South Africa
H.C. Wainwright maintains Buy on Halozyme stock, $72 target - Investing.com Australia
Halozyme sues Merck; FDA blames cuts for Vanda delay - BioPharma Dive
Deep Dive Into Halozyme Therapeutics Stock: Analyst Perspectives (5 Ratings) - Benzinga
Halozyme files lawsuit against Merck over SC Keytruda - The Pharma Letter
Halozyme sues Merck over alleged patent infringement By Investing.com - Investing.com South Africa
Halozyme sues Merck, alleging injectable Keytruda will infringe its patents - Endpoints News
Merck Faces Lawsuit to Block Launch of Easier-to-Use Keytruda - Bloomberg.com
Halozyme Therapeutics (HALO) Files Lawsuit Against Merck Over Patent Infringement - GuruFocus
Merck stock flat despite Halozyme patent suit (MRK:NYSE) - Seeking Alpha
Halozyme Files Patent Infringement Lawsuit Against Merck - Nasdaq
Halozyme sues Merck over alleged patent infringement - Investing.com
Halozyme (HALO) Sues Merck Over Keytruda's Subcutaneous Patent Infringement | HALO Stock News - GuruFocus
Halozyme Therapeutics Sues Merck Over Alleged Patent Infringement - marketscreener.com
Halozyme Sues Merck for Patent Infringement over Subcutaneous Keytruda Formulation | HALO Stock News - GuruFocus
Halozyme Sues Merck for Patent Infringement over Subcutaneous Keytruda Formulation - marketscreener.com
Halozyme Challenges Merck in Patent Battle Over Breakthrough Subcutaneous Keytruda Technology - Stock Titan
Here's How Much You Would Have Made Owning Halozyme Therapeutics Stock In The Last 5 Years - Benzinga
Halozyme Therapeutics (NASDAQ:HALO) Has A Rock Solid Balance Sheet - simplywall.st
If EPS Growth Is Important To You, Halozyme Therapeutics (NASDAQ:HALO) Presents An Opportunity - Yahoo Finance
Biotech Stock Bounces From Support, Shows Relative Strength Amid Volatile Market - MSN
Halozyme Announces FDA Approval of argenx's VYVGART® Hytrulo Pre - GuruFocus
Peering Into Halozyme Therapeutics's Recent Short Interest - Benzinga
Argenx stock rises on FDA nod for Vyvgart Hytrulo (ARGX) - Seeking Alpha
Halozyme Therapeutics Reports FDA Approval for Self-Injectable Syringe Developed in Partnership With Argenx - marketscreener.com
Halozyme :FDA Oks Argenx' VYVGART Hytrulo Prefilled Syringe For Generalized Myasthenia Gravis & CIDP - Nasdaq
Halozyme Announces FDA Approval of argenx's VYVGART® Hytrulo Prefilled Syringe Co-Formulated with ENHANZE® for Self-Injection for Generalized Myasthenia Gravis and Chronic Inflammatory Demyelinating Polyneuropathy - Citizen Tribune
J&J, Halozyme win EU nod for injectable Rybrevant in lung cancer - MSN
argenx Announces FDA Approval of VYVGART Hytrulo Prefilled Syringe for Self-Injection in Generalized Myasthenia Gravis and Chronic Inflammatory Demyelinating Polyneuropathy - GlobeNewswire Inc.
Halozyme Therapeutics (HALO) Gains EU Approval for Injectable Co - GuruFocus
J&J, Halozyme get EU nod for Darzalex SC to treat multiple myeloma - Seeking Alpha
European Commission Approved Subcutaneous Darzalex (Daratumumab) Based Quadruplet Regimen - marketscreener.com
Halozyme Reports EC Approval For Indication Extension Of DARZALEX Co-formulated With ENHANZE - Nasdaq
European Commission Approved Subcutaneous DARZALEX® (daratumumab)-based Quadruplet Regimen for the Treatment of Patients with Newly Diagnosed Multiple Myeloma, Regardless of Transplant Eligibility - Quantisnow
Halozyme Therapeutics : Announces Roche Receives FDA Approval For Phesgo™ (Fixed-Dose Combination Of Perjeta® And Herceptin® For Subcutaneous Injection) Utilizing 's ENHANZE® Technology For The Treatment Of Patients With HER2-Positive Bre - MarketScreener
Halozyme Therapeutics : To Receive $10 Million Milestone Payment From Janssen - MarketScreener
Halozyme (HALO) Secures European Approval for J&J Antitumor Inje - GuruFocus
EC approves new lung cancer treatment using Halozyme technology By Investing.com - Investing.com South Africa
European Commission Approves Subcutaneous RYBREVANT® (amivantamab) Co-Formulated with ENHANZE® for the Treatment of Patients with Advanced EGFR-Mutated Non-Small Cell Lung Cancer - The Malaysian Reserve
Halozyme Says EC Approved Subcutaneous Rybrevant For Advanced EGFR-Mutated NSCLC - Nasdaq
EC approves new lung cancer treatment using Halozyme technology - Investing.com
European Commission Approves Subcutaneous Rybrevant® (Amivantamab) - MarketScreener
KLP Kapitalforvaltning AS Makes New Investment in Halozyme Therapeutics, Inc. (NASDAQ:HALO) - MarketBeat
Halozyme Therapeutics director Jeffrey Henderson sells $32,217 in stock - Investing.com Australia
Halozyme Therapeutics director Jeffrey Henderson sells $32,217 in stock By Investing.com - Investing.com South Africa
0.24%
36.06%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):